DB:1U5

Stock Analysis Report

Executive Summary

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform.

Snowflake

Fundamentals

Flawless balance sheet with limited growth.

Risks

  • Wave Life Sciences has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Wave Life Sciences's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

26.0%

DB:1U5

1.2%

DE Pharmaceuticals

1.8%

DE Market


1 Year Return

-48.0%

DB:1U5

1.9%

DE Pharmaceuticals

-3.5%

DE Market

1U5 underperformed the Pharmaceuticals industry which returned 1.9% over the past year.

1U5 underperformed the Market in Germany which returned -3.5% over the past year.


Share holder returns

1U5IndustryMarket
7 Day26.0%1.2%1.8%
30 Day29.4%4.8%7.2%
90 Day-3.3%17.8%3.5%
1 Year-48.0%-48.0%5.3%1.9%-0.5%-3.5%
3 Yearn/a-4.7%-12.7%20.6%10.3%
5 Yearn/a-7.0%-18.6%30.7%12.8%

Price Volatility Vs. Market

How volatile is Wave Life Sciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Wave Life Sciences undervalued based on future cash flows and its price relative to the stock market?

5.86x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Wave Life Sciences to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Wave Life Sciences to establish if it is available at substantial discount.


Price Based on Earnings

Wave Life Sciences is loss making, we can't compare its value to the DE Pharmaceuticals industry average.

Wave Life Sciences is loss making, we can't compare the value of its earnings to the Germany market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Wave Life Sciences, we can't assess if its growth is good value.


Price Based on Value of Assets

Wave Life Sciences is overvalued based on assets compared to the DE Pharmaceuticals industry average.


Next Steps

Future Growth

How is Wave Life Sciences expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

7.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Wave Life Sciences's revenue is expected to grow significantly at over 20% yearly.

Wave Life Sciences is not considered high growth as it is expected to be loss making for the next 1-3 years.

Wave Life Sciences's revenue growth is expected to exceed the Germany market average.

Unable to compare Wave Life Sciences's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Wave Life Sciences's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Wave Life Sciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Wave Life Sciences performed over the past 5 years?

-52.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Wave Life Sciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Wave Life Sciences's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Wave Life Sciences's 1-year growth to the DE Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Wave Life Sciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Wave Life Sciences has efficiently used its assets last year compared to the DE Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Wave Life Sciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Wave Life Sciences's financial position?


Financial Position Analysis

Wave Life Sciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Wave Life Sciences's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Wave Life Sciences has no debt.

Wave Life Sciences currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Low level of unsold assets.

Wave Life Sciences has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Wave Life Sciences has sufficient cash runway for 1.6 years based on current free cash flow.

Wave Life Sciences has sufficient cash runway for 1.6 years if free cash flow continues to grow at historical rates of 25.8% each year.


Next Steps

Dividend

What is Wave Life Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Wave Life Sciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Wave Life Sciences's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Wave Life Sciences has not reported any payouts.

Unable to verify if Wave Life Sciences's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Wave Life Sciences has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Wave Life Sciences's salary, the management and board of directors tenure and is there insider trading?

3.1yrs

Average management tenure


CEO

Paul Bolno (45yo)

5.8yrs

Tenure

US$5,839,966

Compensation

Dr. Paul B. Bolno, M.D., MBA has been the Chief Executive Officer and President of WAVE Life Sciences Ltd. since December 2013. Prior to joining WAVE, Dr. Bolno served at GlaxoSmithKline from 2009 to 2013  ...


CEO Compensation Analysis

Paul's remuneration is higher than average for companies of similar size in Germany.

Paul's compensation has increased whilst company is loss making.


Management Age and Tenure

3.1yrs

Average Tenure

50.5yo

Average Age

The tenure for the Wave Life Sciences management team is about average.


Board Age and Tenure

5.4yrs

Average Tenure

54yo

Average Age

The tenure for the Wave Life Sciences board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$6,655,42614 Mar 19
Kagoshima Development
EntityCompany
Shares157,791
Max PriceUS$46.47
BuyUS$8,814,00428 Jan 19
RA Capital Management, LLC
EntityCompany
Shares263,158
Max PriceUS$33.49
SellUS$515,00516 Nov 18
Gregory Verdine
EntityIndividual
Role
Member of the Board of Directors
Director
Shares15,000
Max PriceUS$34.92

Ownership Breakdown


Management Team

  • Greg Verdine (60yo)

    Director

    • Tenure: 6.2yrs
    • Compensation: US$387.05k
  • Chandra Vargeese (58yo)

    Senior Vice President of Drug Discovery

    • Tenure: 5.1yrs
    • Compensation: US$2.17m
  • Kyle Moran (48yo)

    Senior Vice President of Operations & Business Analytics

    • Tenure: 2.6yrs
  • Tushar Misra

    Senior Vice President of Technical Operations

    • Tenure: 0.8yrs
  • Keith Regnante (49yo)

    Chief Financial Officer

    • Tenure: 3.1yrs
    • Compensation: US$1.69m
  • Clare Carmichael (59yo)

    Chief Human Resources Officer

    • Tenure: 0yrs
  • Linda Rockett

    General Counsel

    • Tenure: 3.3yrs
  • Paul Bolno (45yo)

    President

    • Tenure: 5.8yrs
    • Compensation: US$5.84m
  • Chris Francis (41yo)

    Senior VP of Corporate Development & Head of Emerging Areas

    • Tenure: 2.7yrs
    • Compensation: US$1.68m
  • Mike Panzara (52yo)

    Chief Medical Officer

    • Tenure: 0.8yrs
    • Compensation: US$2.22m

Board Members

  • Greg Verdine (60yo)

    Director

    • Tenure: 6.2yrs
    • Compensation: US$387.05k
  • Mark H. Corrigan (61yo)

    Independent Director

    • Tenure: 0yrs
  • Christian Henry (51yo)

    Chairperson

    • Tenure: 1.9yrs
    • Compensation: US$295.05k
  • Koji Miura (69yo)

    Independent Director

    • Tenure: 6.9yrs
    • Compensation: US$244.55k
  • Ad Rawcliffe (47yo)

    Independent Director

    • Tenure: 2.6yrs
    • Compensation: US$244.55k
  • Peter Kolchinsky (42yo)

    Independent Director

    • Tenure: 4.7yrs
    • Compensation: US$246.05k
  • Ken Takanashi (55yo)

    Independent Director

    • Tenure: 7.2yrs
    • Compensation: US$246.05k
  • Heidi Wagner (54yo)

    Independent Director

    • Tenure: 0yrs
  • Paul Bolno (45yo)

    President

    • Tenure: 5.8yrs
    • Compensation: US$5.84m
  • Amy Pott

    Independent Director

    • Tenure: 0yrs

Company Information

Wave Life Sciences Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Wave Life Sciences Ltd.
  • Ticker: 1U5
  • Exchange: DB
  • Founded: 2012
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$939.288m
  • Listing Market Cap: US$854.094m
  • Shares outstanding: 34.28m
  • Website: https://www.wavelifesciences.com

Number of Employees


Location

  • Wave Life Sciences Ltd.
  • Marina One East Tower
  • No. 12-00, 7 Straits View
  • Singapore
  • 18936
  • Singapore

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
WVENasdaqGM (Nasdaq Global Market)YesOrdinary SharesUSUSDNov 2015
1U5DB (Deutsche Boerse AG)YesOrdinary SharesDEEURNov 2015

Biography

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The compan ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/16 22:13
End of Day Share Price2019/09/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.